Digital chronic disease management platform Health2Sync has recently raised $20 million in a Series C funding round led by Taiwania Capital. Wistron, Pegatron, BE Health Ventures, ABIES Capital, and Cathay Venture also joined the round.

This latest investment brings its total capital raised since its founding in 2013 to over $30 million. 

WHAT IT'S FOR

In a media release, the company said it plans to deploy its latest funds for the development of new disease management programs, including a digital weight loss program that will make the highly demanded GLP-1 medications accessible.   

With the new funding, it also plans to further its expansion into strategic markets, particularly Japan, South Korea, and Australia, and deepen its use of AI to elevate patient and provider experience.

Meanwhile, it is set to introduce Insultrate, an insulin self-titration software-as-a-medical device, outside Taiwan.

The fresh funds will also support Health2Sync's preparations for a public listing in Taiwan.

THE LARGER TREND

Over the past few years, Health2Sync has secured partnerships with big pharma and large health systems across Asia-Pacific as part of its expansion. Most recently, it piloted a digital diabetes screening and coaching program in Singapore together with Abbott and the Health Promotion Board. In December, it launched a digital diabetes management program with Western Sydney Diabetes in Australia, featuring the use of its mobile application. 

Besides diabetes, Health2Sync also has a digital program for chronic kidney disease.